Stock Price Forecast

Dec. 1, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Akouos Inc chart...

About the Company

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

Exchange

NASDAQ

Website

akouos.com

$M

Total Revenue

69

Employees

$491M

Market Capitalization

-1.40

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AKUS News

Deaf Boy Can Now Hear After New Gene Treatment

1mon ago, source: Hosted on MSN

The study, sponsored by Akouos, Inc, is part of ongoing research to understand the long-term effects of this gene therapy on hearing improvement. Read Also: Iconic Food Chain Closes Due To Crime ...

Akouos to Present at Upcoming September Virtual Investor Conferences

1mon ago, source: ADVFN

Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide ...

Peter W. Sonsini's Net Worth

4d ago, source: Benzinga.com

Who is Peter W. Sonsini? Peter W. Sonsini has an estimated net worth of $898 Million. This is based on reported shares across multiple companies, which include Desktop Metal, Inc., Cascadian ...

Sofinnova Venture Partners X, L.P.'s Net Worth

1mon ago, source: Benzinga.com

Inc., and Akouos, Inc.. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools ...

CV THERAPEUTICS RAISES $13M IN PRIVATE FINANCING

1mon ago, source: BioWorld

Shares of Corbus Pharmaceuticals Inc. (NASDAQ:CRBP) doubled on opening Jan. 26 and ended the day up a whopping 249% as investors got a look at data from a... Hookipa Pharma Inc.’s nearly $1 billion ...

Welcome to Inc.'s Directory of B2B Excellence

4mon ago, source: Inc

They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.

STIHL Inc.

7mon ago, source: Forbes

This company has paid to receive expanded profile features. About STIHL Inc. Virginia-based STIHL Inc. is the U.S. affiliate for the global STIHL group and the manufacturer of the number one ...

Items Tagged with 'immunotherapies'

2mon ago, source: BioWorld

It struck a second deal with San Francisco-based 3T Biosciences Inc. to develop cancer immunotherapies, which builds on an earlier collaboration formed last year. Combined, the two deals are worth ...

Snap Inc Class A

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BBAI BigBear.ai Holdings, Inc.

4d ago, source: Seeking Alpha

BigBear.ai Holdings, Inc. provides artificial intelligence and machine learning for decision support. The company operates through two segments, Cyber & Engineering and Analytics. The Cyber ...

Block Inc.

5mon ago, source: Wall Street Journal

1 Day SQ -1.32% DJIA -0.49% S&P 500 -0.65% Technology -1.75% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum ...

Apple Inc.

20d ago, source: Wall Street Journal

1 Day AAPL 2.56% DJIA 0.30% S&P 500 1.05% Technology -1.75% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...